OraSure Q4 revenue falls 29%, core business down 22%

OraSure Technologies

25/02/2026 21:47

Overview

Diagnostic test maker's Q4 revenue fell 29% yr/yr

Core business revenue decreased 22% yr/yr in Q4

Company continued $40 mln share repurchase program

Outlook

OraSure guides Q1 2026 revenue between $26 mln and $29 mln

Company anticipates U.S. regulatory clearance for new diagnostic products in 2026

Result Drivers

CORE BUSINESS DECLINE - Core business revenue fell 22% due to lower HIV test sales and a drop in Sample Management Solutions revenue from a major customer

Company press release: ID:nGNX8f1pdC

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
$26.80 mln
Q4 Gross Margin
41.00%
Q4 Adjusted Operating Income
-$15.20 mln
Q4 Operating Income
-$20.10 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for OraSure Technologies Inc is $4.50, about 59.6% above its February 24 closing price of $2.82

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)